212 related articles for article (PubMed ID: 32576385)
1. Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.
Chang HL; Wei PJ; Wu KL; Huang HL; Yang CJ
Lung Cancer; 2020 Aug; 146():376-377. PubMed ID: 32576385
[No Abstract] [Full Text] [Related]
2. Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
Maio M; Hamid O; Larkin J; Covre A; Altomonte M; Calabrò L; Vardhana SA; Robert C; Ibrahim R; Anichini A; Wolchok JD; Giacomo AMD
Clin Cancer Res; 2020 Aug; 26(16):4201-4205. PubMed ID: 32540850
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic?
Chu C; Sun Y; Pan Y
Oral Oncol; 2020 Aug; 107():104860. PubMed ID: 32571643
[No Abstract] [Full Text] [Related]
4. Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?
Di Noia V; D'Aveni A; Squadroni M; Beretta GD; Ceresoli GL
Lung Cancer; 2020 Jul; 145():208-210. PubMed ID: 32439211
[No Abstract] [Full Text] [Related]
5. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
Ottaviano M; Curvietto M; Rescigno P; Tortora M; Palmieri G; Giannarelli D; Aieta M; Assalone P; Attademo L; Avallone A; Bloise F; Bosso D; Borzillo V; Buono G; Calderoni G; Caputo F; Cartenì G; Cavallero D; Cavo A; Ciardiello F; Conca R; Conteduca V; De Falco S; De Felice M; De Laurentiis M; De Placido P; De Placido S; De Santo I; De Stefano A; Della Corte CM; Di Franco R; Di Lauro V; Fabbrocini A; Federico P; Festino L; Giordano P; Giuliano M; Gridelli C; Grimaldi AM; Lia M; Marretta AL; Massa V; Mennitto A; Merler S; Merz V; Messina C; Messina M; Milano M; Minisini AM; Montesarchio V; Morabito A; Morgillo F; Mucci B; Nappi L; Napolitano F; Paciolla I; Pagliuca M; Palmieri G; Parola S; Pepe S; Petrillo A; Piantedosi F; Piccin L; Picozzi F; Pietroluongo E; Pignata S; Prati V; Riccio V; Rosanova M; Rossi A; Russo A; Salati M; Santabarbara G; Sbrana A; Simeone E; Silvestri A; Spada M; Tarantino P; Taveggia P; Tomei F; Vincenzo T; Trapani D; Trojanello C; Vanella V; Vari S; Ventriglia J; Vitale MG; Vitiello F; Vivaldi C; von Arx C; Zacchi F; Zampiva I; Zivi A; Daniele B; Ascierto PA;
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060148
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.
Wu Q; Chu Q; Zhang H; Yang B; He X; Zhong Y; Yuan X; Chua MLK; Xie C
Cancer Commun (Lond); 2020 Aug; 40(8):374-379. PubMed ID: 32666636
[No Abstract] [Full Text] [Related]
7. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
Ghosh N; Tirpack A; Chan KK; Bass AR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
[TBL] [Abstract][Full Text] [Related]
8. Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment.
Rossi E; Schinzari G; Tortora G
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32699182
[TBL] [Abstract][Full Text] [Related]
9. Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.
Rossi D
Lung Cancer; 2020 Jul; 145():83-84. PubMed ID: 32416433
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Infection in Patients with Lung Cancer: Current Clinical Context.
Isea de la Viña J; Ortega Granados AL; Alcázar-Navarrete B
Arch Bronconeumol (Engl Ed); 2020 Oct; 56(10):684. PubMed ID: 32336565
[No Abstract] [Full Text] [Related]
11. Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.
Demaria O; Carvelli J; Batista L; Thibult ML; Morel A; André P; Morel Y; Vély F; Vivier E
Cell Mol Immunol; 2020 Sep; 17(9):995-997. PubMed ID: 32612152
[No Abstract] [Full Text] [Related]
12. Challenges in lung cancer therapy during the COVID-19 pandemic.
Calabrò L; Peters S; Soria JC; Di Giacomo AM; Barlesi F; Covre A; Altomonte M; Vegni V; Gridelli C; Reck M; Rizvi N; Maio M
Lancet Respir Med; 2020 Jun; 8(6):542-544. PubMed ID: 32278368
[No Abstract] [Full Text] [Related]
13. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
Baumann T; Delgado J; Montserrat E
Leukemia; 2020 Jul; 34(7):1954-1956. PubMed ID: 32433507
[No Abstract] [Full Text] [Related]
14. COVID-19: the use of immunotherapy in metastatic lung cancer.
Davis AP; Boyer M; Lee JH; Kao SC
Immunotherapy; 2020 Jun; 12(8):545-548. PubMed ID: 32349579
[No Abstract] [Full Text] [Related]
15. Rethinking Clinical Trials Reform During the COVID-19 Pandemic.
Nabhan C; Choueiri TK; Mato AR
JAMA Oncol; 2020 Sep; 6(9):1327-1329. PubMed ID: 32761101
[No Abstract] [Full Text] [Related]
16. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
Pickles OJ; Lee LYW; Starkey T; Freeman-Mills L; Olsson-Brown A; Cheng V; Hughes DJ; Lee A; Purshouse K; Middleton G
Br J Cancer; 2020 Sep; 123(5):691-693. PubMed ID: 32546835
[TBL] [Abstract][Full Text] [Related]
17. Importance of Environmental Factors on Production of Computationally- Defined Natural Molecules against COVID-19 Pandemic.
Abouleish M; El-Keblawy A; Mosa KA; Soliman SSM
Curr Top Med Chem; 2020; 20(22):1958-1961. PubMed ID: 33040729
[No Abstract] [Full Text] [Related]
18. [Not Available].
Nau JY
Rev Med Suisse; 2020 Mar; 16(685):510-511. PubMed ID: 32167254
[No Abstract] [Full Text] [Related]
19. The treatment and outcome of a pulmonary sarcomatoid carcinoma patient infected with SARS-CoV-2.
Wang K; Liu Y; Hu T; Liu Y; Liu C
Lung Cancer; 2020 Aug; 146():373-375. PubMed ID: 32563532
[No Abstract] [Full Text] [Related]
20. Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations and Outcomes.
Cinar P; Cox J; Kamal A; Bickel K; Krzyzanowska M; Armitage J; Ganti AK; Ward J; Wong S; Lonial S; Bosserman L
JCO Oncol Pract; 2020 Aug; 16(8):431-434. PubMed ID: 32463764
[No Abstract] [Full Text] [Related]
[Next] [New Search]
